Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 19,984

Document Document Title
WO/2019/115781A1
The present invention relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit t...  
WO/2018/151861A9
Provided herein are methods for determining if a compound has potential efficacy for the treatment for a specific symptom domain of schizophrenia, such as for example, the treatment of a negative symptom of schizophrenia. In addition, pr...  
WO/2019/106146A1
Compounds of formula (I) and related aspects.  
WO/2019/106156A1
Compounds of formula (I): (I) and related aspects.  
WO/2019/105933A1
Compounds of the formula (I), (I) wherein the substituents are as defined in claim 1, useful as pesticides, and especially fungicides.  
WO/2019/094851A1
Disclosed are methods of treating ataxia by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.  
WO/2019/087548A1
Provided is a fluorine-containing ether compound which is capable of forming a lubricating layer that has excellent wear resistance even if the thickness thereof is thin, and which is suitable as a material for a lubricant for magnetic r...  
WO/2019/090076A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2019/080882A1
Disclosed are a compound as shown in formula (I), a pharmaceutical composition comprising the compound of formula (I), and the use of the compound and pharmaceutical composition in the preparation of an HDAC inhibitor drug. The compound ...  
WO/2019/081575A1
The present inventions concerns use of a specific methoxyacrylate compound to control mosquitoes, and vector control products comprising that methoxyacrylate compound, in particular the invention relates to a substrate, to a composition,...  
WO/2019/080842A1
Provided in the present invention is a compound of formula (I) or pharmaceutically acceptable salt, solvate or metabolite thereof, which can be used for treating and/or preventing ischemia-reperfusion injury and related diseases, acute r...  
WO/2018/064119A8
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.  
WO/2019/074007A1
A polymerizable liquid crystal compound which is represented by general formula (1). (In general formula (1), the symbols are as defined in the description.)  
WO/2019/068817A1
The present invention relates to novel antiviral compounds with specific stereoconfiguration, especially to specific novel enantiomers, to a process for their preparation and to their use as medicaments, in particular as antiviral medica...  
WO/2019/070093A1
The present disclosure provides a compound of general Formula (I) having c-abl kinase inhibitory activity or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method useful to treat or ...  
WO/2019/070709A1
The present invention provides compounds, compositions and methods for treating and/or preventing a flavivirus infection by administering such compounds and compositions.  
WO/2019/063710A1
The invention relates to resorcinol-based compounds of formula (I), to the salts, solvates, optical and/or geometrical isomers thereof, to the use thereof as active agents for depigmenting, lightening and/ or bleaching keratin materials,...  
WO/2019/064961A1
Provided are: a photosensitive resin composition having high tolerance for focus depth in the formation of a punched pattern; a resist film which is a solidified product of the photosensitive resin composition; a method for forming a pat...  
WO/2019/060147A1
The present disclosure encompasses crystalline polymorphs of Ponesimod, processes for preparation thereof, and pharmaceutical compositions thereof.  
WO/2019/055825A1
The current methods and compositions provide for therapeutic approaches to treating hepatocellular carcinoma (HCC) and other types of cancer including, for example, pancreatic and colon cancer. Accordingly, certain aspects of the disclos...  
WO/2019/054944A1
The present invention relates to compounds of general Formula (I), and/or tautomers, enantiomers, solvates, hydrates, and pharmaceutically acceptable salts thereof. The present invention also relates to compounds of Formula (I) for use i...  
WO/2019/053427A1
There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof,wherein the ring containing Q1to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.  
WO/2019/046931A1
Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions invol...  
WO/2019/051465A1
This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.  
WO/2019/051207A1
Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.  
WO/2019/051322A1
Improved processes for the preparation of tubulysin compounds, tubulysin drug linker compounds, and their intermediates are disclosed.  
WO/2019/044863A1
The present invention provides a cured product which is obtained by curing a curable composition that contains a compound represented by general formula 1, and which has a birefringence ∆n (587 nm) satisfying 0.00 ≤ ∆n (587 nm) ≤...  
WO/2019/043610A1
The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates...  
WO/2019/046668A1
Provided herein are thiazole carboxamide protein secretin inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compo...  
WO/2019/028164A1
Disclosed are compounds that promote spinogenesis, are capable of reducing the neural toxicity of beta-amyloid peptides, and/or reduce the symptoms of traumatic brain injury in a patient.  
WO/2019/024635A1
Provided are a 1,3-di-substituted ketene compound having a structure as represented by formula (I) and an application thereof. Such a type of compound primarily activates peroxisome proliferator-activated receptor (PPAR) α, and also act...  
WO/2019/023147A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, c...  
WO/2019/021202A1
6-Thio derivatives of D-luciferin, also referred to as D-thioluciferins, having the general structure of Formula (I) are provided. Methods for synthesising D-luciferin, its derivatives, and their related 2-cyanobenzothiazole precursors a...  
WO/2019/023145A1
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, ...  
WO/2019/016826A1
Disclosed are novel 5-[4-(2-biphenyl-4-yl-2-oxo-ethoxy)-benzylidene]-thiazolidin e-2,4-dione compounds of general formula (I), their pharmaceutically acceptable salts, solvates their synthesis and uses thereof, to pharmaceutical composit...  
WO/2019/016393A1
The invention relates to a compound which is a thiazole derivative of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, Formula (A), Z, L, X, m, n and p are as defined herein. The compounds a...  
WO/2019/016293A1
The present invention relates to certain compounds of formula (I) wherein - Ar is (Ar1) or (Ar2) and to their uses as antibacterial agents. The invention further relates to methods of treatment of bacterial infection with such compounds,...  
WO/2019/014315A1
This application is directed to inhibitors of RAD51, and methods for their use, such as to treat or prevent conditions involving mitochondrial defects.  
WO/2019/013981A1
The present teachings relate to a fluoro-containing compound, a composition thereof, a method of using the compound or the composition in treating a disease, and a method of preparing the compound. In a particular example, the compound i...  
WO/2019/011176A1
Disclosed is the use of a 2-trifluoromethylbenzenesulfonamide derivative as shown in formula (I) as a URAT1 inhibitor, in particular as a therapeutic agent for a disorder related to abnormal uric acid levels.  
WO/2019/002173A1
The present invention relates to a compound of formula (I): wherein the meanings for the various substituents are as disclosed in the description, having dual pharmacological activity towards both the α2δ subunit, in particular the α2...  
WO/2019/000494A1
Provided is a fluorene-based organic electroluminescent compound, having the following structure: The compound has good thermal stability, high luminous efficiency, and high luminous purity, and can be used for manufacturing organic elec...  
WO/2019/002074A1
The present invention provides PRMT5 inhibiting compounds of general formula (I). A compound of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, L1 and L2 are as defined herein, methods of preparing said compounds, intermediate ...  
WO/2019/001416A1
The present invention provides a thiazolinone heterocyclic compound and a preparation method, pharmaceutical composition, and application thereof. The present invention provides an application of the thiazolinone heterocyclic compound in...  
WO/2018/235966A1
The present invention provides a compound which has an excellent inhibitory activity on histone acetyltransferase of EP300 and/or CREBBP, or a pharmacologically acceptable salt of the compound. A compound represented by formula (1) or a ...  
WO/2018/233326A1
A hydrogen sulfide donor in an organic salt form and a preparation method therefor. The hydrogen sulfide donor is a salt structure formed by organic compounds with an alkaline structure and hydrogen sulfide. The hydrogen sulfide donor ha...  
WO/2018/235926A1
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...  
WO/2018/230528A1
Provided are a novel nitrocatechol derivative having COMT inhibitory effect and DDC inhibitory effect or a salt thereof and a medicinal composition comprising the same. A compound represented by general formula (1) or a pharmaceutically ...  
WO/2018/224060A1
The present invention relates to solid forms with an antimicrobial activity comprising a polysaccharide and triiodide, where the triiodide decomposition to iodide and volatile iodine is significantly suppressed by the presence of a stabi...  
WO/2018/221562A1
According to the present invention, it is found that dopamine D2-like receptor agonists acts on a dopamine D2-like receptor in an activated Th cell and thereby inhibits the production of Interleukin-8 (IL-8).  

Matches 1 - 50 out of 19,984